Trial Profile
A Randomized, Double-Masked, Multicenter, Laser-Controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-Therapy in Patients With Visual Impairment Due to Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RESTORE; RESTORE-Ext
- Sponsors Novartis
- 21 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database. (EudraCT2007-004877-24)
- 21 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database. (EudraCT2007-004877-24)
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.